






ORIGINAL RESEARCH

Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events

Peter Willeit , MD, MPhil, PhD*; Calvin Yeang , MD, PhD*; Patrick M. Moriarty, MD; Lena Tschiderer , PhD; Stephen A. Varvel , PhD; Joseph P. McConnell, PhD; Sotirios Tsimikas , MD

BACKGROUND: Conventional "low-density lipoprotein cholesterol (LDL-C)" assays measure cholesterol content in both low-density lipoprotein and lipoprotein(a) particles. To clarify the consequences of this methodological limitation for clinical care, our study aimed to compare associations of "LDL-C" and corrected LDL-C with risk of cardiovascular disease and to assess the impact of this correction on the classification of patients into guideline-recommended LDL-C categories.

METHODS AND RESULTS: Lipoprotein(a) cholesterol content was estimated as 30% of lipoprotein(a) mass and subtracted from "LDL-C" to obtain corrected LDL-C values (LDL-C_{corr30}). Hazard ratios for cardiovascular disease (defined as coronary heart disease, stroke, or coronary revascularization) were quantified by individual-patient-data meta-analysis of 5 statin landmark trials from the Lipoprotein(a) Studies Collaboration (18 043 patients; 5390 events; 4.7 years median follow-up). When comparing top versus bottom quartiles, the multivariable-adjusted hazard ratio for cardiovascular disease was significant for "LDL-C" (1.17; 95% CI, 1.05–1.31; $P=0.005$) but not for LDL-C_{corr30} (1.07; 95% CI, 0.93–1.22; $P=0.362$). In a routine laboratory database involving 531 144 patients, reclassification of patients across guideline-recommended LDL-C categories when using LDL-C_{corr30} was assessed. In "LDL-C" categories of 70 to <100, 100 to <130, 130 to <190, and ≥ 190 mg/dL, significant proportions (95% CI) of participants were reassigned to lower LDL-C categories when LDL-C_{corr30} was used: 30.2% (30.0%–30.4%), 35.1% (34.9%–35.4%), 32.9% (32.6%–33.1%), and 41.1% (40.0%–42.2%), respectively.

CONCLUSIONS: "LDL-C" was associated with incident cardiovascular disease only when lipoprotein(a) cholesterol content was included in its measurement. Refinement in techniques to accurately measure LDL-C, particularly in patients with elevated lipoprotein(a) levels, is warranted to assign risk to the responsible lipoproteins.

Key Words: cholesterol ■ guidelines ■ lipoprotein(a) ■ low-density lipoprotein

Management of low-density lipoprotein cholesterol (LDL-C) is the cornerstone in cardiovascular disease (CVD) prevention. LDL-C is used as a screening test, diagnostic marker for familial hypercholesterolemia (FH), target of therapy for diet, drugs, and apheresis, and goal for adequate care in the outpatient clinic, after hospital discharge and in clinical guidelines.^{1,2} It is generally accepted that the laboratory

measure "LDL-C" is an accurate representation of what is being measured. However, because of methodological limitations, all available clinical methods that measure and report "LDL-C" are affected by the presence of the cholesterol content of lipoprotein(a) (Lp[a]-C).^{3,4} This includes all methods of calculated or measured "LDL-C," including the Friedewald formula, ultracentrifugation, or direct LDL-C methods.^{5,6} The main reason

Correspondence to: Sotirios Tsimikas, MD, Vascular Medicine Program, Sulpizio Cardiovascular Center, University of California, San Diego, 9500 Gilman Dr, BSB 1080, La Jolla, CA 92093-0682. E-mail stsimikas@ucsd.edu.

Supplementary material for this article is available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.016318>.

*Dr. Willeit and Dr. Yeang contributed equally to this work.

For Sources of Funding and Disclosures, see page 9.

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- It is underappreciated that clinical measurements of “low-density lipoprotein cholesterol (LDL-C)” include the cholesterol content of both low-density lipoprotein and lipoprotein(a).
- An individual-patient-data meta-analysis of 5 landmark statin trials consisting of 18 043 patients demonstrated that LDL-C corrected for its lipoprotein(a)-cholesterol content did not predict cardiovascular disease events, in contrast to “LDL-C.”
- The percentage contribution of lipoprotein(a)-cholesterol to “LDL-C,” and proportion of individuals assigned to lower LDL-C categories, based on “LDL-C” corrected for its lipoprotein(a)-cholesterol content was determined in 531 144 patients.

What Are the Clinical Implications?

- Low-density lipoprotein-mediated cardiovascular disease risk is imprecisely described by currently available laboratory measurements of “LDL-C,” which reflects combined low-density lipoprotein- and lipoprotein(a)-mediated risk.
- Low-density lipoprotein and lipoprotein(a) have unique biological properties and respond differently to lipid-lowering therapies; therefore, refining “LDL-C” into its distinct components may lead to improved cardiovascular disease prognostication and management.

Nonstandard Abbreviations and Acronyms

FH	familial hypercholesterolemia
“LDL-C”	clinical laboratory measurement that includes the cholesterol content of both low-density lipoprotein and lipoprotein(a)
LDL-C_{corr}	LDL-C corrected for the cholesterol content of lipoprotein(a)
Lp(a)-C_{corr30}	LDL-C corrected for the cholesterol content of lipoprotein(a), assuming that 30% of measured lipoprotein(a) mass is cholesterol
Lp(a)-C	cholesterol content on Lp(a)

for this is the inability to separate low-density lipoprotein from lipoprotein(a) particles and quantify cholesterol content separately on these particles.

Lipoprotein(a) is composed of apolipoprotein(a), apolipoprotein B-100, cholesteryl esters, free

cholesterol, phospholipids, and carbohydrates on apolipoprotein(a).⁷ On the basis of observations from multiple laboratories with expertise in lipoprotein(a) biochemical analyses, the cholesterol content of lipoprotein(a) constitutes ≈30% to 45% of total lipoprotein(a) mass.^{8–13} This implicates that if lipoprotein(a) mass levels are low (eg, <10 mg/dL), the contribution of Lp(a)-C to plasma LDL-C is small (<5 mg/dL). However, if lipoprotein(a) mass is high (eg, 150 mg/dL), its contribution to “LDL-C” can be significant (45–67.5 mg/dL).³ By inference, true LDL-C will be significantly lower in patients with elevated lipoprotein(a) levels.

There is currently no gold standard method available to measure true LDL-C or Lp(a)-C. The main reason for this is that lipoprotein(a) is a low-density lipoprotein (LDL)-containing particle and thus its density overlaps with that of LDL, creating challenges in separating the respective particles without overlap for measuring their cholesterol content. In this study, we estimated corrected LDL-C (LDL-C_{corr}) using parameters derived from prior biochemical studies.^{8–14} We hypothesized that the predictive value of LDL-C_{corr} would be diminished by removing the Lp(a)-C content from LDL-C. Furthermore, we quantified how patients might be re-assigned into different LDL-C categories if the Lp(a)-C content was removed. We conducted the present analysis in a meta-analysis from the Lipoprotein(a) Studies Collaboration of 18 043 patients with 5390 CVD events derived from 5 landmark statin trials and in a US clinical laboratory database of 531 144 patients.

METHODS

Data Availability

Because of contractual obligations, data used to generate the findings of this study are not available to third parties.

Correction of “LDL-C” for Lp(a)-C Content

In the principal analysis, Lp(a)-C was estimated as 30% of total lipoprotein(a) mass and was then subtracted from “LDL-C” to obtain corrected LDL-C values (LDL-C_{corr30}). Supplementary sensitivity analyses assumed 20%, 25%, or 45% of total lipoprotein(a) mass to bracket a broad range of varying proportions of cholesterol content in the lipoprotein(a) particle.

Statin Trials in the Lipoprotein(a) Studies Collaboration

To assess associations of “LDL-C” versus LDL-C_{corr} with CVD outcomes, we analyzed data from the Lipoprotein(a) Studies Collaboration, a consortium collating data on lipoprotein(a), traditional CVD risk factors, and incident CVD events.¹⁵ For inclusion in

the present analysis, randomized controlled trials were eligible if they had information on lipoprotein(a), LDL-C, age, sex, history of CVD, history of diabetes mellitus, smoking, systolic blood pressure, and high-density lipoprotein cholesterol at study entry. The trials CARDS (Collaborative Atorvastatin Diabetes Study), 4D (German Diabetes and Dialysis Study), LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) Study, MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Study, and 4S (Scandinavian Simvastatin Survival Study) fulfilled the prespecified inclusion criteria (because of contractual agreements, the trial JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) could not be included in this analysis).^{16–20} The trials represent the gamut of LDL-C-mediated high-risk groups, including patients on dialysis, diabetes mellitus, high-risk primary prevention, secondary prevention, acute coronary syndromes, and secondary prevention with high LDL-C in the FH range.

Clinical Laboratory Database

The clinical laboratory database was derived from Health Diagnostic Laboratory and included individuals with first time lipoprotein(a) levels.^{21,22} Lipoprotein(a) mass was most often ordered as part of a comprehensive panel of biomarkers assessing CVD risk (~98% of the time). Fasting serum samples were analyzed for lipoprotein(a) mass levels in 531 144 individuals from January 1, 2010, to December 31, 2014. Lipoprotein(a) mass assays were performed using a commercially available immunoturbidimetric assay (Denka Seiken Co Ltd, Tokyo, Japan), which is highly concordant with the reference method.¹² Institutional review board approval for studies using deidentified and aggregated laboratory data was obtained from the Copernicus Group. Serum samples were kept at 4°C and were analyzed within 4 days of collection.

Statistical Analysis

Descriptive summaries are provided as counts with percentages, means with SDs, or medians with interquartile ranges. Because “LDL-C” and LDL-C_{corr30} values were approximately normally distributed, values were not transformed for analysis. Cross-sectional associations of LDL-C parameters were assessed with linear regression for continuous variables and logistic regression for dichotomous variables. Hazard ratios (HRs) for the combined CVD end point (defined as coronary heart disease, stroke, or coronary revascularization procedures) were estimated first within each contributing trial, before pooling them across trials with multivariate random-effects meta-analysis²³ (for details on end point definition, see Table S1). We chose this

“2-stage approach” (rather than a single Cox model stratified by trial) because we anticipated differences between trials inherent in their designs, such as inclusion criteria (eg, age, sex, and “LDL-C” at trial entry) and type and dosages of statin intervention. HRs were estimated using Cox proportional-hazard regression models adjusted for age, sex, history of CVD, diabetes mellitus, smoking, systolic blood pressure, and high-density lipoprotein cholesterol, and stratified by trial arm (thereby allowing hazard functions to differ between patients allocated statin versus those allocated placebo). When estimating associations across quartiles of “LDL-C” or LDL-C_{corr30}, quartiles were defined within each trial based on the trial-specific distribution. The assumption for the proportionality of hazards was tested using Schoenfeld residuals and was met. The I^2 statistic was calculated as a measure of between-trial heterogeneity.²⁴ Finally, the added predictive value of LDL-C parameters was quantified using metrics of risk discrimination and reclassification.^{25,26} In absence of established risk categories in high-risk populations, reclassification was assessed across the categories of <20%, 20% to <30%, 30% to <40%, and ≥40% of 5-year predicted risk. Analyses were performed using Stata version 15.1 MP and involved 2-sided statistical tests, a significance level of $P \leq 0.05$, and 95% CIs.

RESULTS

Association With CVD Risk

Table 1 displays the characteristics of patients from the Lipoprotein(a) Studies Collaboration. Mean baseline “LDL-C” concentration across trials ranged from 112 to 188 mg/dL, whereas mean baseline LDL-C_{corr30} ranged from 106 to 183 mg/dL. The pooled mean was 140 mg/dL of “LDL-C” (SD, 29 mg/dL) and 133 mg/dL of LDL-C_{corr30} (SD, 29 mg/dL). Over a median duration of follow-up of 4.7 years, 5390 CVD events were recorded. Values of “LDL-C” and LDL-C_{corr30} were highly correlated, indicated by a pooled Pearson correlation coefficient of 0.96 (95% CI, 0.94–0.97) (Figure S1).

Figure 1 shows multivariable adjusted HRs across quartiles of “LDL-C” and LDL-C_{corr30}. Compared with the bottom quartile of “LDL-C,” patients with “LDL-C” levels in the top quartile had an HR for CVD of 1.17 (95% CI, 1.05–1.31; $P=0.005$). In contrast, there was no significant association between LDL-C_{corr30} and CVD risk, with an HR of 1.07 (95% CI, 0.93–1.22; $P=0.362$). The corresponding HRs for CVD per 1-SD higher concentration (29 mg/dL) were 1.06 (95% CI, 1.02–1.10; $P=0.006$) for “LDL-C” and 1.03 (95% CI, 0.99–1.07; $P=0.090$) for LDL-C_{corr30}. Between-trial heterogeneity in HRs was low to moderate, with point estimates of I^2 values ranging between 0% and 49%. Trial-specific quartile definitions and HRs are provided in Table S2.

Table 1. Characteristics of Patients Involved in the Trials From the Lipoprotein(a) Studies Collaboration

Variables	4D (n = 1224)	CARDS (n = 2232)	LIPID (n = 7862)	MIRACL (n = 2328)	4S (n = 4397)	Total (n = 18 043)
Baseline						
Age, y	66 (8)	62 (8)	61 (8)	65 (11)	59 (7)	62 (8)
Female sex, n (%)	566 (46)	715 (32)	1333 (17)	784 (34)	823 (19)	4221 (23)
History of CVD, n (%)	501 (41)	6 (0)	7862 (100)	2328 (100)	4397 (100)	15 094 (84)
Diabetes mellitus, n (%)	1224 (100)	2232 (100)	676 (89)	503 (22)	200 (5)	4835 (27)
Smoking, n (%)	107 (9)	484 (22)	735 (9)	674 (29)	1127 (26)	3127 (17)
SBP, mm Hg	146 (22)	144 (16)	134 (19)	128 (20)	139 (20)	138 (19)
Total cholesterol, mg/dL	219 (43)	206 (33)	219 (32)	206 (37)	260 (26)	222 (32)
HDL-C, mg/dL	36 (13)	63 (19)	37 (9)	47 (12)	46 (11)	46 (12)
Triglycerides, mg/dL	223 (149–325)	142 (97–195)	140 (104–192)	162 (122–219)	128 (97–159)	142 (106–193)
ApoB, mg/dL	110 (30)	115 (24)	133 (25)	...	116 (18)	119 (23)
Lipoprotein(a), mg/dL	12 (5–42)	9 (5–22)	14 (7–44)	10 (5–29)	10 (4–27)	12 (5–34)
"LDL-C," mg/dL	126 (30)	112 (30)	150 (29)	124 (33)	188 (25)	140 (29)
LDL-C _{corr30} , mg/dL	116 (33)	106 (30)	142 (29)	118 (33)	183 (25)	133 (29)
Follow-up						
Duration of follow-up, y	2.4 (1.4–3.7)	4.0 (3.1–4.7)	5.4 (3.1–6.0)	0.3 (0.3–0.3)	5.3 (3.9–5.5)	4.7 (1.6–5.5)
No. of CVD events	329	154	3039	517	1351	5390

Data shown are means (SDs), medians (interquartile ranges), or counts (percentages). LDL-C_{corr30} was estimated by subtracting 30% of lipoprotein(a) mass from "LDL-C". Descriptive summaries of corrected LDL-C values assuming other proportions of lipoprotein(a) cholesterol content are provided in Table S3. Total means and SDs were calculated by pooling trial-specific estimates with random-effects meta-analysis. 4D indicates German Diabetes and Dialysis Study; 4S, Scandinavian Simvastatin Survival Study; ApoB, apolipoprotein B; CARDS, Collaborative Atorvastatin Diabetes Study; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LIPID, Long-Term Intervention with Pravastatin in Ischaemic Disease Study; MIRACL, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study; and SBP, systolic blood pressure.

Results were similar in sensitivity analyses, assuming a varying cholesterol content between 20%, 25%, or 45% in lipoprotein(a) (Table S3 and Figure S2) and

when distinguishing between patients assigned statin and those assigned placebo (Figure S3). When adjusting HRs of "LDL-C" for baseline log_e lipoprotein(a) rather




Figure 1. Adjusted hazard ratios (HRs) for cardiovascular disease (CVD) risk, according to quartiles of low-density lipoprotein cholesterol (LDL-C) and LDL-C_{corr30} in the contributing statin trials from the Lipoprotein(a) Studies Collaboration (n = 18 043). LDL-C_{corr30} was estimated by subtracting 30% of lipoprotein(a) mass from "LDL-C". Quartiles were defined within each contributing trial based on trial-specific distributions. HRs were adjusted for age, sex, history of CVD, diabetes mellitus, smoking, systolic blood pressure, and high-density lipoprotein cholesterol. P values for trend across quartiles were 0.009 for "LDL-C" and 0.201 for LDL-C_{corr30}. PY indicates person-years.

than using LDL-C_{corr30}, the magnitude of attenuation of the association with CVD risk was smaller (Figure S4).

Added Value for CVD Prediction

Table 2 summarizes improvements in CVD risk prediction by measuring “LDL-C” or LDL-C_{corr30}. The base model containing information on age, sex, history of CVD, diabetes mellitus, smoking, systolic blood pressure, and high-density lipoprotein cholesterol had a C-index of 0.569 (95% CI, 0.561–0.577). This C-index was improved by 0.0030 (*P*=0.021) on addition of “LDL-C” and by 0.0017 (*P*=0.098) on addition of LDL-C_{corr30}. Corresponding net reclassification improvements of 5-year risk were 0.94% (*P*=0.086) and 0.02% (*P*=0.954); estimates for integrated discrimination improvement were 0.00059 (*P*=0.020) and 0.00016 (*P*=0.193), respectively.

Patient Reassignment Into Lower LDL-C Categories

Table 3 summarizes demographic and laboratory characteristics of patients included in the laboratory database stratified by “LDL-C” categories. “LDL-C”

Table 2. Comparative Prediction Value of LDL-C and LDL-C_{corr30} for Future CVD on Top of Other Conventional Risk Factors

Variable	Addition of Information on “LDL-C” Quartiles*	Addition of Information on LDL-C _{corr30} Quartiles*
Risk discrimination		
No. of patients	18 043	18 043
No. of CVD events	5390	5390
C-index change	0.0030	0.0017
95% CI	0.0005 to 0.0056	-0.0003 to 0.0037
<i>P</i> value	0.021	0.098
Reclassification of 5-y risk		
No. of patients	15 715	15 715
No. of CVD events	4360	4360
NRI, %†	0.94	0.02
95% CI, %	-0.13 to 2.02	-0.74 to 0.79
<i>P</i> value	0.086	0.954
IDI	0.00059	0.00016
95% CI	0.00009 to 0.00108	-0.00008 to 0.00040
<i>P</i> value	0.020	0.193

LDL-C_{corr30} was estimated by subtracting 30% of lipoprotein(a) mass from “LDL-C.” CVD indicates cardiovascular disease; IDI, integrated discrimination improvement; LDL-C, low-density lipoprotein cholesterol; NRI, net reclassification index.

*Addition to a model containing age, sex, history of CVD, diabetes mellitus, smoking, systolic blood pressure, and high-density lipoprotein cholesterol, stratified by trial and trial arm.

†Reclassification across the categories of predicted risk of <20%, 20% to <30%, 30% to <40%, and ≥40%.

was higher at younger age (*t*=-114; *P*<0.0001) and in female patients (*z*=50; *P*<0.0001). All other variables we assessed were positively associated with “LDL-C,” with associations being the strongest for LDL-C_{corr30} (*t*=1399), apolipoprotein B-100 (*t*=1188), total cholesterol (*t*=968), LDL particle number (*t*=820), lipoprotein(a) mass (*t*=64), and Lp(a)-C₃₀ (*t*=64) (all *P*<0.0001).

Figure 2 depicts analyses by deciles of lipoprotein(a) mass, with the highest decile further divided in thirds. Across these groups, median concentration of Lp(a)-C₃₀ ranged from 0.9 to 48.3 mg/dL. The contribution of Lp(a)-C_{corr30} to “LDL-C” increased gradually from 0.8% in the bottom group to 46.6% in the top group. On correction of “LDL-C” for Lp(a)-C_{corr30} to obtain LDL-C_{corr30}, median LDL-C concentration was reduced from 96 to 95 mg/dL in the bottom group and from 108 to 57 mg/dL in the top group. Sensitivity analyses that assumed a cholesterol content of 20%, 25%, or 45% in lipoprotein(a) are shown in Table S4 and Figure S5.

Figure 3 summarizes the reassignment of patients on correction of “LDL-C” to LDL-C_{corr30} across clinical LDL-C categories. The proportions of patients reclassified to a lower category were 30.2% (95% CI, 30.0%–30.4%) in the group with LDL-C of 70 to <100 mg/dL, 35.1% (95% CI, 34.9%–35.4%) in the group with “LDL-C” of 100 to <130 mg/dL, and 32.9% (95% CI, 32.6%–33.1%) in the group with “LDL-C” of 130 to <190 mg/dL. Most important, in the clinical risk category for FH with “LDL-C” ≥190 mg/dL, 41.1% of patients (95% CI, 40.0%–42.2%) were reassigned to an “LDL-C” of <190 mg/dL. Reassignment results when assuming variable percentages of cholesterol content in lipoprotein(a) are provided in Figure S6.

DISCUSSION

The present study suggests that the CVD risk attributed to “LDL-C” is potentiated by the additional contribution of Lp(a)-C. Furthermore, estimating true LDL-C by correcting for the Lp(a)-C content reassigns 30% to 41% of patients into lower traditional LDL-C categories. Figure 4 displays the heterogeneity with respect to the relative contributions of true LDL and lipoprotein(a) in individuals with similar laboratory-measured LDL-C. LDL and lipoprotein(a) have distinct biological properties and respond differently to lipid-lowering therapies, which cannot be appreciated if they are evaluated as a composite within LDL-C. Although the contribution of Lp(a)-C to what is measured as “LDL-C” may be less relevant in individuals with low lipoprotein(a) mass, in 20% of the population with lipoprotein(a) mass >50 mg/dL, ≥14% of the cholesterol attributed to LDL is instead Lp(a)-C. Moreover, >28% of what is measured as “LDL-C” may come from Lp(a)-C in 10% of the population

Table 3. Characteristics of Patients From the Clinical Laboratory Database

Variables	Categories of "LDL-C," mg/dL					t Statistic for Trend [†]	P Value for trend [†]
	<70 (n = 83 807)	70- $<$ 100 (n = 178 245)	100- $<$ 130 (n = 157 576)	130- $<$ 190 (n = 103 597)	\geq 190 (n = 7,919)		
Age, y	61 (15)	57 (15)	54 (14)	54 (13)	55 (13)	-114	<0.0001
Female sex, n (%)	36 759 (44)	92 035 (52)	84 860 (54)	57 118 (55)	4830 (61)	50 [†]	<0.0001 [†]
Total cholesterol, mg/dL	136 (31)	166 (23)	196 (23)	235 (28)	304 (42)	968	<0.0001
HDL-C, mg/dL	50 (17)	53 (16)	55 (15)	55 (14)	59 (14)	78	<0.0001
Triglycerides, mg/dL	92 (66-136)	101 (72-146)	111 (80-158)	130 (95-179)	155 (115-213)	141	<0.0001
ApoB, mg/dL	60 (12)	79 (12)	99 (13)	124 (17)	166 (25)	1188	<0.0001
LDL particles, nmol/L	924 (293)	1299 (316)	1652 (361)	2099 (449)	2808 (486)	820	<0.0001
Lipoprotein(a) mass, mg/dL	14 (6-36)	16 (7-46)	17 (8-48)	20 (8-56)	25 (10-72)	64	<0.0001
Lp(a)-C ₃₀ , mg/dL	4 (2-11)	5 (2-14)	5 (2-14)	6 (2-17)	8 (3-22)	64	<0.0001
"LDL-C," mg/dL	57 (10)	85 (9)	113 (9)	149 (15)	211 (26)	NA	NA
LDL-C _{corr30} , mg/dL	49 (13)	75 (14)	103 (15)	138 (19)	197 (29)	1399	<0.0001

Data shown are means (SDs), medians (interquartile ranges), or counts (percentages). Lp(a)-C₃₀ was estimated as 30% of lipoprotein(a) mass. LDL-C_{corr30} was estimated by subtracting Lp(a)-C₃₀ from "LDL-C". Of 531 144 people, 15 had a missing value of age, triglycerides, total cholesterol, or HDL-C, which was mean imputed for this analysis. Descriptive summaries of corrected LDL-C values assuming other proportions of lipoprotein(a) cholesterol content are provided in Table S4. ApoB indicates apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and NA, not available.

[†]t Statistics and P values for trend were calculated using linear regression, unless specified otherwise.

[†]Numbers are z statistics and P values for trend, calculated using logistic regression.

with lipoprotein(a) mass >100 mg/dL. Refinement in techniques to accurately measure LDL-C, particularly in patients with elevated lipoprotein(a) levels, is warranted to accurately attribute risk to the responsible lipoproteins.

It is important to emphasize that no matter how LDL-C is measured or calculated, it remains a validated risk predictor and target of therapy, irrespective of its biochemical composition. However, LDL-C risk thresholds and therapeutic goals as currently used in clinical

medicine are more accurately expressed as "intermediate-density lipoprotein cholesterol+LDL-C+Lp(a)-C." For the sake of accuracy and clarity in understanding what is being reflected in an "LDL-C" measurement, it is imperative to precisely measure and define each component. In future analyses, it will be important to validate the current findings with biochemically robust methods to measure true LDL-C and to reassess the contribution of each lipoprotein alone and both combined in CVD risk. With the more frequent use of




Figure 2. Estimated concentration of Lp(a)-C₃₀ (A), its percentage contribution to "low-density lipoprotein cholesterol (LDL-C)" (B), and concentration of "LDL-C" vs. LDL-C_{corr30} values (C) according to different levels of lipoprotein(a) mass. Analysis is based on the Health Diagnostic Laboratory data. Lp(a)-C₃₀ was estimated as 30% of lipoprotein(a) (Lp[a]) mass. LDL-C_{corr30} was calculated by subtracting Lp(a)-C₃₀ from "LDL-C". In panel C, LDL-C is in gray and LDL-C_{corr30} in red. Groups plotted are deciles of Lp(a) mass, with the top decile further divided into thirds. IQR indicates interquartile range.

"LDL-C", mg/dL	No. of people in categories of LDL-C _{corr30} , mg/dL					Reclassified to lower category	
	<70	70-<100	100-<130	130-<190	≥190	No. of people	Row % (95% CI)
	<70	83,807	0	0	0	0	NA
70-<100	53,815	124,430	0	0	0	53,815	30.2% (30.0-30.4)
100-<130	4,936	50,424	102,216	0	0	55,360	35.1% (34.9-35.4)
130-<190	227	2,945	30,863	69,562	0	34,035	32.9% (32.6-33.1)
≥190	0	1	32	3,221	4,665	3,254	41.1% (40.0-42.2)

Figure 3. Reassignment to lower low-density lipoprotein cholesterol (LDL-C) categories on correction to LDL-C_{corr30}.

Analysis is based on the Health Diagnostic Laboratory data. LDL-C_{corr30} was estimated by subtracting 30% of lipoprotein(a) mass from "LDL-C". NA indicates not available.

PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors in clinical medicine that lower "LDL-C" to low levels, and with the advent of new therapies that lower lipoprotein(a),²⁷ it will be important for proper interpretation and assignment of benefit to changes in accurately measured lipoproteins.

There are several clinical implications to the current findings. First, these observations apply to almost all

patients in whom a lipid panel is measured because absence of circulating lipoprotein(a) is extremely rare.²⁸ The methodological limitations of current measures/calculations of LDL-C particularly affect patients with elevated lipoprotein(a), because the contribution of their lipoprotein(a) mass to LDL-C will be proportionally higher as lipoprotein(a) mass increases. Lipoprotein(a) concentration >30 mg/dL is present in ~35% of




Figure 4. Conceptual rendition of the relationship of laboratory-measured low-density lipoprotein cholesterol (LDL-C) in several scenarios of differing lipoprotein(a) (Lp[a]) mass levels. The true LDL-C will vary significantly according to the Lp(a)-cholesterol contribution, and cannot be ascertained from current laboratory methods.

The traditional fasting lipid profile in a patient is shown in the left with total cholesterol of 150 mg/dL, composed of high-density lipoprotein cholesterol (HDL-C) 50 mg/dL, very LDL-C (VLDL-C) 30 mg/dL, "LDL-C" 70 mg/dL, and Lp(a) mass 0 mg/dL, and thus Lp(a)-C 0 mg/dL. As the Lp(a) mass increases, the Lp(a)-C increases proportionally, and the estimated LDL-C is also reduced. In the extreme, in a patient with Lp(a) mass of 210 mg/dL, the laboratory-measured LDL-C would be recorded as 70 mg/dL because of inability of current assays to differentiate between LDL-C and Lp(a)-C, but the true LDL-C is closer to 0 mg/dL. This illustration assumes intermediate-density lipoprotein cholesterol is 0 in the fasting state.

patients in the United States²¹ and similar numbers in Europe²⁹, and there are ≈1.4 billion people globally with lipoprotein(a) levels >50 mg/dL.³⁰

Second, our data suggest that CVD risk is imprecisely depicted by “LDL-C.” For example, an “LDL-C” of “70 mg/dL” may represent 2 different patients: one with a lipoprotein(a) mass of 15 mg/dL, Lp(a)-C of 5 mg/dL, and true LDL-C of 65 mg/dL, or another with a lipoprotein(a) mass of 210 mg/dL, Lp(a)-C of 70 mg/dL, and true LDL-C of 0 mg/dL. Despite having identical “LDL-C” values, these 2 individuals would be expected to have unique risk profiles (Figure 4). In a recent analysis of the Copenhagen cohorts, the HR for cardiovascular mortality was 1.18 for every 15-mg/dL increase in Lp(a)-C.³¹ In contrast, the HR for the same outcome was only 1.07 for every 15-mg/dL increase in LDL-C. This finding supports a more granular understanding of the components comprising “LDL-C” for improved risk prediction. At a population level, differential lifelong exposure to LDL-C levels as low as 10 mg/dL results in substantial differences in CVD. This suggests that the contribution of Lp(a)-C to CVD events, which is directly related to lipoprotein(a) mass that is genetically determined and contributes risk from birth, can be substantial, even with modest elevations of Lp(a)-C levels. For example, lipoprotein(a) levels at upper limit of normal at 30 mg/dL may contribute as much as 9 to 13.5 mg/dL of cholesterol to the LDL-C measurement. This value is similar to loss-of-function PCSK9 mutations associated with lifelong lower risk of CVD.³²

Third, many physicians aim to achieve an “LDL-C” <70 mg/dL for high-risk patients, which is further supported by guidelines.¹ Thus, many patients with “LDL-C” ≥70 mg/dL and elevated lipoprotein(a) while on statin therapy, in fact, already have true LDL-C significantly lower than 70 mg/dL. The recommendation to further increase LDL-C-lowering therapy in such patients may not accurately reflect whether true LDL-C versus lipoprotein(a) reflects additional residual risk. Because statins tend to increase lipoprotein(a),³³ further increase in statin dosage in a patient with already true low LDL-C may be counterproductive. Similarly, in patients being treated with PCSK9 inhibitors that achieve exceedingly low LDL-C (ie, <20 mg/dL), true LDL-C levels may be at or near zero if lipoprotein(a) is elevated, as we suggested recently.³

Fourth, should lipoprotein(a) mass and/or cholesterol content be part of the FH diagnosis? Using a more accurate measurement of LDL-C would result in many subjects not meeting the criterion of “LDL-C” ≥190 mg/dL used in many scores unless the Lp(a)-C was included in the measurement.³⁴ The concept to formally include lipoprotein(a) in the diagnosis of FH is consistent with studies showing a higher risk of major adverse cardiovascular events if patients with FH have concomitantly elevated lipoprotein(a) levels.³⁵

Fifth, the meta-analysis included a wide range of patients receiving different statins and further reflecting their use in a wide range of CVD prevention cohorts. Accurately quantitating true LDL-C without its content of Lp(a)-C will be important in defining the magnitude of benefit from “LDL-C” lowering agents, particularly in patients with elevated lipoprotein(a), which may represent up to a third of patients in the population and in recent clinical trials^{36,37} who are more likely to have a true LDL-C that is lower than their LDL-C laboratory measurement.

It is important to clarify that Lp(a)-C risk is not equivalent to lipoprotein(a) mass/molar concentration mediated risk, because lipoprotein(a) additionally contains the apolipoprotein B-100 component, the potentially thrombogenic apolipoprotein(a) peptide, as well as proinflammatory oxidized phospholipids that are significantly overrepresented on lipoprotein(a) versus LDL particles.^{38,39} These factors may additionally contribute to risk that is not reflected in its cholesterol content. In fact, lipoprotein(a) mass has been shown to be more predictive than Lp(a)-C when measured in the same patients.¹⁰

The primary objective of this study was to estimate the clinical impact of Lp(a)-C's contribution to what is measured as “LDL-C” and raise awareness to this highly underappreciated caveat of the “LDL-C” biomarker. This study, in isolation, was not intended to provide guidance on clinical practice, but rather to demonstrate the clinical need for accurately defining the contribution of true LDL versus lipoprotein(a) toward the risk attributed to what is currently measured and reported as LDL-C.

Limitations of this study include that because accurate measures of Lp(a)-C are not clinically available, Lp(a)-C was estimated and thus LDL-C_{corr30} was based on established biochemical studies by assuming a proportion of 30% of lipoprotein(a) mass. Individual patients may have variable Lp(a)-C levels on lipoprotein(a) mass that may alter the estimates; thus, in a sensitivity analysis, we bracketed the ranges reported in the literature to account for potential interindividual variability. Moreover, most assays for lipoprotein(a) mass, including the ones described in this study, are sensitive to apolipoprotein(a) isoform size, resulting in overestimation of lipoprotein(a) mass when apolipoprotein(a) isoforms are large (associated with lower lipoprotein[a] levels) and underestimation of lipoprotein(a) mass when apolipoprotein(a) isoforms are small (associated with higher lipoprotein[a] levels). In our study, assay sensitivity to apolipoprotein(a) isoforms may have led to imperfect correction of “LDL-C” for Lp(a)-C and results may be even more pronounced when using isoform-independent assays. Last, there are inaccuracies with commonly used “LDL-C” quantitation methods that may be independent of lipoprotein(a). Compared with

the reference method, the Friedewald method is inaccurate when plasma triglycerides are elevated. There can also be significant biases between various direct “LDL-C” assays and the reference method, especially in patients with CVD.⁴⁰ When assays directly measuring Lp(a)-C are developed in the future, these results would need to be validated empirically in individuals with “LDL-C” determined by the reference method. It is also emphasized that it is difficult to correct for LDL-C when lipoprotein(a) is reported in molar concentration of apolipoprotein(a), rather than mass of entire lipoprotein(a) particle, emphasizing the need for an accurate, empirical measure of Lp(a)-C rather than estimated Lp(a)-C. Finally, the current analysis focused on baseline lipid variables before initiation of statin therapy. Whether the relationship of lipoprotein(a) mass to cholesterol remains similar following statin, PCSK9 inhibitor and antisense therapy to lipoprotein(a) needs to be evaluated in future studies.

In conclusion, our findings provide insights that the predictive value of “LDL-C” is potentiated by its Lp(a)-C content. This study provides a rationale to develop improved methods to accurately quantify LDL-C. Additional clinical investigations are needed to more accurately assign CVD risk to the responsible lipoproteins and to assess the true effect of LDL-C-modifying therapies.

ARTICLE INFORMATION

Received May 2, 2020; accepted August 24, 2020.

Affiliations

From the Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria (P.W., L.T.); Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK (P.W.); Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, La Jolla, CA (C.Y., S.T.); Division of Clinical Pharmacology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, MO (P.M.M.); and Salveo Diagnostics, Inc, Richmond, VA (S.A.V., J.P.M.).

Acknowledgments

We would like to thank the sponsors and principal investigators of the statin trials included in the meta-analysis for their contribution of individual patient data from their trials: Collaborating investigators of the Lipoprotein(a) Studies Collaboration: Florian Kronenberg, Christiane Drechsler, Christoph Wannier (German Diabetes and Dialysis Study [4D] trial); Helen M. Colhoun (Collaborative Atorvastatin Diabetes Study [CARDS] trial); Paul J. Nestel, John Simes, Andrew M. Tonkin (Long-Term Intervention with Pravastatin in Ischaemic Disease [LIPID] trial); Gregory G. Schwartz, Anders G. Olsson (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering [MIRACL] trial); Terje R. Pederson (Scandinavian Simvastatin Survival Study [4S] trial).

Sources of Funding

S.T. has research support in part from the Fondation Leducq. C.Y. is supported by a postdoctoral fellowship grant for the American Heart Association (17POST33660462). P.W. and L.T. are supported by a grant from the Dr.-Johannes-and-Hertha-Tuba-Foundation.

Disclosures

P.W. reports consultancy fees from Novartis Pharmaceuticals. P.M.M. has served as an advisor/consultant to Amgen, Regeneron, Sanofi, RegenXBio, Duke Clinical Research, Alexion, Esperion, Eliaz Therapeutics, and Ionis;

speaker bureau for Amgen, Sanofi, and Regeneron; and research support from Regeneron, Sanofi, Amgen, Ionis, Catabasis, Pfizer, Novartis, Kaneka, and Stage 2 Innovations. S.A.V. and J.P.McC. are employees of Salveo Diagnostics. S.T. is a co-inventor and receives royalties from patents owned by UCSD on oxidation-specific antibodies and of biomarkers related to oxidized lipoproteins and is a co-founder and has an equity interest in Oxitope, Inc and its affiliates (“Oxitope”) as well as in Kleanthi Diagnostics, LLC (“Kleanthi”). Although these relationships have been identified for conflict of interest management based on the overall scope of the project and its potential benefit to Oxitope and Kleanthi, the research findings included in this particular publication may not necessarily relate to the interests of Oxitope and Kleanthi. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. The remaining authors have no disclosures to report.

Supplementary Materials

Tables S1–S4

Figures S1–S6

REFERENCES

- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41:111–188.
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation*. 2019;139:e1082–e1143.
- Yeang C, Witztum JL, Tsimikas S. “LDL-C” = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. *Curr Opin Lipidol*. 2015;26:169–178.
- Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, Watts GF, Boren J, Baum H, Bruckert E, et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol: a consensus statement from EAS and EFLM. *Clin. Chem*. 2018;64:1006–1033.
- Bairaktari E, Elisaf M, Tzallas C, Karabina SA, Tselepis AD, Siamopoulos KC, Tsolas O. Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients(1). *Clin Biochem*. 2001;34:593–602.
- Martin SS, Giugliano RP, Murphy SA, Wasserman SM, Stein EA, Ceska R, Lopez-Miranda J, Georgiev B, Lorenzatti AJ, Tikkanen MJ, et al. Comparison of low-density lipoprotein cholesterol assessment by Martin/Hopkins estimation, Friedewald estimation, and preparative ultracentrifugation: insights from the FOURIER trial. *JAMA Cardiology*. 2018;3:749–753.
- Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein(a). *J Lipid Res*. 2016;57:1339–1359.
- Fless GM, Snyder ML, Furbee JW Jr, Garcia-Hedo MT, Mora R. Subunit composition of lipoprotein(a) protein. *Biochemistry*. 1994;33:13492–13501.
- Seman LJ, Jenner JL, McNamara JR, Schaefer EJ. Quantification of lipoprotein(a) in plasma by assaying cholesterol in lectin-bound plasma fraction. *Clin. Chem*. 1994;40:400–403.
- Lamon-Fava S, Marcovina SM, Albers JJ, Kennedy H, Deluca C, White CC, Cupples LA, McNamara JR, Seman LJ, Bongard V, et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. *J Lipid Res*. 2011;52:1181–1187.
- Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PW, Castelli WP, Schaefer EJ. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. *Circulation*. 1993;87:1135–1141.
- Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, Couderc R, Dati F, Rifai N, Sakurabayashi I, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). *Clin Chem*. 2000;46:1956–1967.

13. Kinpara K, Okada H, Yoneyama A, Okubo M, Murase T. Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. *Clin Chim Acta*. 2011;412:1783–1787.
14. Albers JJ, Hazzard WR. Immunochemical quantification of human plasma Lp(a) lipoprotein. *Lipids*. 1974;9:15–26.
15. Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. *Lancet*. 2018;392:1311–1320.
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344(8934):1383–1389.
17. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med* 1998;339:1349–1357.
18. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA*. 2001;285:1711–1718.
19. Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med*. 2005;353:238–248.
20. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*. 2004;364:685–696.
21. Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. *Arterioscler Thromb Vasc Biol*. 2016;36:2239–2245.
22. Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients. *Arterioscler Thromb Vasc Biol*. 2017;37:580–588.
23. Thompson S, Kaptoge S, White I, Wood A, Perry P, Danesh J. Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. *Int J Epidemiol*. 2010;39:1345–1359.
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21:1539–1558.
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med*. 2008;27(2):157–172; discussion 207–212.
26. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology*. 2010;21:128–138.
27. O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Ceska R, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. *Circulation*. 2019;139:1483–1492.
28. Emdin CA, Khera AV, Natarajan P, Klarin D, Won HH, Peloso GM, Stitzel NO, Nomura A, Zekavat SM, Bick AG, et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. *J Am Coll Cardiol*. 2016;68:2761–2772.
29. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarencu P, Catapano A, Descamps OS, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J*. 2010;31:2844–2853.
30. Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. *J Am Coll Cardiol*. 2018;71:177–192.
31. Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. *Eur Heart J*. 2019;40:2760–2770.
32. Ference BA. Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. *Curr Opin Lipidol*. 2015;26:566–571.
33. Tsimikas S, Gordts P, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. *Eur Heart J*. 2019;41(24):2275–2284. 10.1093/eurheartj/ehz310.
34. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *J Lipid Res*. 2016;57:1953–1975.
35. Alonso R, Andres E, Mata N, Fuentes-Jimenez F, Badimon L, Lopez-Miranda J, Padro T, Muniz O, Diaz-Diaz JL, Mauri M, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. *J Am Coll Cardiol*. 2014;63:1982–1989.
36. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *Lancet*. 2017;390:1962–1971.
37. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–2107.
38. Byun YS, Lee JH, Arsenaault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S, TNT Trial Investigators. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. *J Am Coll Cardiol*. 2015;65:1286–1295.
39. Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S, Investigators ST. Oxidized phospholipids on apolipoprotein b-100 and recurrent ischemic events following stroke or transient ischemic attack. *J Am Coll Cardiol*. 2017;69:147–158.
40. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. *Clin Chem*. 2010;56:977–986.

SUPPLEMENTAL MATERIAL

Table S1. Definition of the combined cardiovascular disease endpoint in the contributing statin trials from the Lipoprotein(a) Studies Collaboration.

Components of the combined cardiovascular disease endpoint	4D	CARDS	LIPID	MIRACL	4S
Fatal coronary heart disease	●	●	●	●	●
Non-fatal myocardial infarction	●	●	●	●	●
Unstable angina	-	●	●	●	-
Resuscitated cardiac arrest	-	●	-	-	●
Stroke	●	●	●	●	-
Coronary revascularization	●	●	-	●	●

Table S2. Trial-specific quartile definitions and hazard ratios for CVD in the contributing statin trials from the Lipoprotein(a) Studies Collaboration.

		Quartile 1	Quartile 2	Quartile 3	Quartile 4
"LDL-C"					
4D	Range, mg/dL	≤104	105-123	124-144	≥145
	HR (95% CI)	[Reference]	0.97 (0.92-1.02)	1.18 (1.12-1.24)	1.20 (1.14-1.26)
CARDS	Range, mg/dL	≤92	92-113	114-134	≥134
	HR (95% CI)	[Reference]	1.31 (1.16-1.47)	1.46 (1.30-1.65)	1.76 (1.57-1.97)
LIPID	Range, mg/dL	≤131	131-150	150-170	≥170
	HR (95% CI)	[Reference]	1.04 (1.03-1.04)	1.07 (1.07-1.08)	1.14 (1.13-1.14)
MIRACL	Range, mg/dL	≤101	102-122	123-146	≥147
	HR (95% CI)	[Reference]	1.08 (1.05-1.11)	0.93 (0.90-0.96)	0.99 (0.96-1.02)
4S	Range, mg/dL	≤170	170-187	189-207	≥208
	HR (95% CI)	[Reference]	1.20 (1.19-1.21)	1.10 (1.09-1.12)	1.25 (1.24-1.27)
LDL-C_{corr30}					
4D	Range, mg/dL	≤94	94-115	116-137	≥137
	HR (95% CI)	[Reference]	0.96 (0.91-1.02)	1.20 (1.14-1.26)	1.04 (0.99-1.10)
CARDS	Range, mg/dL	≤86	86-106	106-127	≥127
	HR (95% CI)	[Reference]	1.22 (1.08-1.37)	1.35 (1.20-1.51)	1.60 (1.43-1.79)
LIPID	Range, mg/dL	≤122	122-141	141-161	≥162
	HR (95% CI)	[Reference]	1.04 (1.04-1.05)	1.02 (1.02-1.03)	1.08 (1.08-1.09)
MIRACL	Range, mg/dL	≤94	94-115	115-139	≥140
	HR (95% CI)	[Reference]	0.83 (0.80-0.85)	0.90 (0.87-0.92)	0.83 (0.81-0.86)
4S	Range, mg/dL	≤165	165-183	183-200	≥200
	HR (95% CI)	[Reference]	1.15 (1.13-1.16)	1.10 (1.09-1.12)	1.16 (1.14-1.17)

LDL-C_{corr30} was estimated by subtracting 30% of Lp(a) mass from LDL-C. Quartiles were defined within each contributing trial based on trial-specific distributions. Hazard ratios were adjusted for age, sex, prior cardiovascular disease, diabetes, smoking, systolic blood pressure, and high-density lipoprotein cholesterol. CI=confidence interval; HR=hazard ratio.

Table S3. Descriptive summary of corrected LDL-C in the contributing statin trials from the Lipoprotein(a) Studies Collaboration assuming varying proportions of Lp(a) cholesterol content.

Variables	4D (n=1,224)	CARDS (n=2,232)	LIPID (n=7,862)	MIRACL (n=2,328)	4S (n=4,397)	Total (n=18,043)
LDL-C _{corr20} , mg/dL	119 (31)	108 (30)	145 (28)	120 (33)	185 (25)	135 (29)
LDL-C _{corr25} , mg/dL	117 (32)	107 (30)	143 (29)	119 (33)	184 (25)	134 (29)
LDL-C _{corr45} , mg/dL	111 (36)	103 (31)	138 (30)	114 (34)	180 (26)	129 (30)



Data shown are means (standard deviations). LDL-C_{corr20}, LDL-C_{corr25}, and LDL-C_{corr45} were estimated by subtracting 20%, 25% and 45% of Lp(a) mass from “LDL-C”, respectively. Total means and standard deviations were calculated by pooling trial-specific estimates with random-effects meta-analysis.

Table S4. Descriptive summary of Lp(a)-C and corrected LDL-C in patients from the clinical laboratory database assuming varying proportions of Lp(a) cholesterol content.

Variables	Categories of LDL-C					t statistic for trend ^a	P value for trend ^a
	<70 mg/dL (n=83,807)	70-<100 mg/dL (n=178,245)	100-<130 mg/dL (n=157,576)	130-<190 mg/dL (n=103,597)	≥190 mg/dL (n=7,919)		
Lp(a)-C ₂₀ , mg/dL	3 (1-7)	3 (1-9)	3 (2-10)	4 (2-11)	5 (2-14)	64	<0.0001
Lp(a)-C ₂₅ , mg/dL	4 (2-9)	4 (2-12)	4 (2-12)	5 (2-14)	6 (3-18)	64	<0.0001
Lp(a)-C ₄₅ , mg/dL	6 (3-16)	7 (3-21)	8 (4-22)	9 (4-25)	11 (5-32)	64	<0.0001
LDL-C _{corr20} , mg/dL	51 (11)	78 (12)	107 (12)	141 (17)	202 (27)	1,670	<0.0001
LDL-C _{corr25} , mg/dL	50 (12)	77 (13)	105 (13)	139 (18)	200 (28)	1,531	<0.0001
LDL-C _{corr45} , mg/dL	45 (16)	70 (19)	98 (20)	132 (24)	190 (34)	1,084	<0.0001


Data shown are means (standard deviations) or medians (interquartile ranges). Lp(a)-C₂₀, Lp(a)-C₂₅, and Lp(a)-C₄₅ were estimated as 20%, 25%, and 45% of Lp(a) mass, respectively. LDL-C_{corr20}, LDL-C_{corr25}, and LDL-C_{corr45} were estimated by subtracting Lp(a)-C₂₀, Lp(a)-C₂₅, and Lp(a)-C₄₅ from “LDL-C”, respectively. ^at statistics and P values for trend were calculated using linear regression.

Figure S1. Scatter plots (A) and Pearson correlation coefficients of LDL-C and LDL-C_{corr30} values in the contributing statin trials from the Lipoprotein(a) Studies Collaboration (n=18,043).




In Panel (b), the pooled Pearson correlation coefficient was estimated using random-effects meta-analysis using z-transformed study-specific correlation coefficients. CI=confidence interval.

Figure S2. Adjusted hazard ratios for cardiovascular disease risk according to quartiles of LDL-C_{corr20}, LDL-C_{corr25}, and LDL-C_{corr45} in the contributing statin trials from the Lipoprotein(a) Studies Collaboration (n=18,043).




LDL-C_{corr20}, LDL-C_{corr25}, and LDL-C_{corr45} were estimated by subtracting 20%, 25% and 45% of Lp(a) mass from “LDL-C”, respectively. Quartiles were defined within each contributing trial based on trial-specific distributions. Hazard ratios were adjusted for age, sex, prior cardiovascular disease, diabetes, smoking, systolic blood pressure, and high-density lipoprotein cholesterol. CI=confidence interval; PY=person-years.

Figure S3. Adjusted hazard ratios for cardiovascular disease risk for quartiles of LDL-C and LDL-C_{corr30} according to allocation of statin vs. placebo in the contributing statin trials from the Lipoprotein(a) Studies Collaboration (n=18,043).




LDL-C_{corr30} was estimated by subtracting 30% of Lp(a) mass from "LDL-C". Quartiles were defined within each contributing trial based on trial-specific distributions. Hazard ratios were adjusted for age, sex, prior cardiovascular disease, diabetes, smoking, systolic blood pressure, and high-density lipoprotein cholesterol. CI=confidence interval; HR=hazard ratio.

Figure S4. Association of “LDL-C” with cardiovascular disease risk in a multivariable model further adjusted for $\log_e \text{Lp(a)}$ in the contributing statin trials from the Lipoprotein(a) Studies Collaboration (n=18,043).



“LDL-C” quartiles were defined within each contributing trial based on trial-specific distributions. Multivariable adjustment models were adjusted for age, sex, prior cardiovascular disease, diabetes, smoking, systolic blood pressure, high-density lipoprotein cholesterol, and $\log_e \text{Lp(a)}$. CI=confidence interval; CVD=cardiovascular disease; HR=hazard ratio; PY=person years; SD=standard deviation.

Figure S5. Estimated Lp(a)-C₂₀, Lp(a)-C₂₅, and Lp(a)-C₄₅, contribution to LDL-C, and corrected LDL-C values in patients from the clinical laboratory database assuming varying proportions of Lp(a) cholesterol content.



Analysis is based on the Health Diagnostic Laboratory data. Lp(a)-C₂₀, Lp(a)-C₂₅, and Lp(a)-C₄₅ were estimated as 20%, 25%, and 45% of Lp(a) mass, respectively. LDL-C_{corr20}, LDL-C_{corr25}, and LDL-C_{corr45} were estimated by subtracting Lp(a)-C₂₀, Lp(a)-C₂₅, and Lp(a)-C₄₅ from "LDL-C", respectively. Groups plotted are deciles of Lp(a) mass, with the top decile further divided into thirds. IQR=interquartile-range.

Figure S6. Reassignment to lower LDL-C categories upon correction to LDL-C_{corr20}, LDL-C_{corr25}, and LDL-C_{corr45} of patients from the clinical laboratory database.

(A) Reclassification with LDL-C_{corr20}								
		No. of people in categories of LDL-C_{corr20} mg/dL					Reclassified to lower category	
		<70	70-<100	100-<130	130-<190	≥190	No. of people	Row % (95% CI)
„LDL-C“, mg/dL	<70	83,807	0	0	0	0	NA	NA
	70-<100	37,949	140,296	0	0	0	37,949	21.3% (21.1-21.5)
	100-<130	1,029	39,860	116,687	0	0	40,889	25.9% (25.7-26.2)
	130-<190	13	629	24,461	78,494	0	25,103	24.2% (24.0-24.5)
	≥190	0	0	0	2,573	5,346	2,573	32.5% (31.5-33.5)

(B) Reclassification with LDL-C_{corr25}								
		No. of people in categories of LDL-C_{corr25} mg/dL					Reclassified to lower category	
		<70	70-<100	100-<130	130-<190	≥190	No. of people	Row % (95% CI)
„LDL-C“, mg/dL	<70	83,807	0	0	0	0	NA	NA
	70-<100	46,078	132,167	0	0	0	46,078	25.9% (25.6-26.1)
	100-<130	2,648	45,701	109,227	0	0	48,349	30.7% (30.5-30.9)
	130-<190	42	1,631	27,935	73,989	0	29,608	28.6% (28.3-28.9)
	≥190	0	0	8	2,891	5,020	2,899	36.6% (35.5-37.7)

(C) Reclassification with LDL-C_{corr45}								
		No. of people in categories of LDL-C_{corr45} mg/dL					Reclassified to lower category	
		<70	70-<100	100-<130	130-<190	≥190	No. of people	Row % (95% CI)
„LDL-C“, mg/dL	<70	83,807	0	0	0	0	NA	NA
	70-<100	70,483	107,762	0	0	0	70,483	39.5% (39.3-39.8)
	100-<130	15,051	55,184	87,341	0	0	70,235	44.6% (44.3-44.8)
	130-<190	1,832	8,186	33,866	59,713	0	43,884	42.4% (42.1-42.7)
	≥190	6	41	240	3,661	3,971	3,948	49.9% (48.7-51.0)

Analysis is based on the Health Diagnostic Laboratory data. Lp(a)-C₂₀, Lp(a)-C₂₅, and Lp(a)-C₄₅ were estimated as 20%, 25%, and 45% of Lp(a) mass, respectively. LDL-C_{corr20}, LDL-C_{corr25}, and LDL-C_{corr45} were estimated by subtracting Lp(a)-C₂₀, Lp(a)-C₂₅, and Lp(a)-C₄₅ from “LDL-C”, respectively. CI=confidence interval; NA=not available.